Re: Singh et  al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785)

This report consisted of results from 2 substudies. Substudy 1 showed statistically significantly better visual outcomes in those on nepafenac; substudy 2 failed to reach many of the same results. This finding is similar to 2 parallel studies of nepafenac 0.1% in patients with diabetic retinopathy undergoing cataract surgery where both studies found anatomic benefit,2,3 but one did not show significant visual benefit.
Source: Ophthalmology - Category: Opthalmology Authors: Tags: Correspondence Source Type: research